Navigation Links
BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available

ARLINGTON, Va., May 5 /PRNewswire/ -- BioInformatics, LLC announces the release of its newest report, Capitalizing on New Opportunities for Stem Cell Products. Despite a sluggish economy and cuts being made to laboratory budgets, the market for stem cell research products is expected to increase substantially over the next several years to $688.9 M in 2009 and just under one billion at the end of 2011. Suppliers of stem cell related products are in need of a fast, accurate assessment of new opportunities in the stem cell research products market. In this report, BioInformatics, LLC (, the premier research and advisory firm serving the life science market, fielded a detailed 60-question survey to scientists worldwide about their current--and planned--areas of stem cell research, usage of stem cell products and preferred suppliers.

The report will be available at pre-release pricing until May 17, 2009. This special pricing is at a significant reduction off the regular pricing which will take effect on Monday, May 18, 2009.

Life science suppliers can use this study to determine areas poised for growth (i.e., the market for stem cell culture media, sera, supplements and cell lines) in the stem cell research market, identify potential key competitors (including percentage of products purchased from each major supplier), and plan a long-term strategy to secure a leading position in this expanding market. The report includes detailed market share estimates across major stem cell product categories by market segment, geographic region and top suppliers.

In this report, scientists specify percentage of stem cell culture products purchased from each of the following suppliers:

    BD Biosciences (a part of Becton, Dickinson and Co., NYSE:  BDX)
    Life Technologies (Nasdaq:  LIFE)
    Lonza (SWX: LONN)
    Millipore (NYSE:   MIL)
    Miltenyi Biotec
    R&D Systems (division of TECHNE Corp., Nasdaq:  TECH)
    Sigma-Aldrich (divisions: SAFC Biosciences, Nasdaq:  SIAL)
    Stem Cell Sciences (AIM: STEM)
    Stemcell Technologies
    Thermo Fisher Scientific (Hyclone, NYSE:   TMO)
    Zen Bio

As with any valuable research tool, it is important to obtain a better understanding of how stem cells are used in the lab and in particular, what differentiated cell types are of major interest. Although it may not come as a surprise to suppliers that the majority of respondents differentiate their stem cells into hematopoeitic and epithelial cells, other cell types are expected to be of increasing interest over the next couple of years. By 2011, osteogenic cells in particular, but also endothelial, cardiomyocytes, chondrocytes, and dendritic cells are projected to be differentiated states as common as hematopoeitic and epithelial cells. These findings have implications for product development as the cell types of interest will dictate the kinds of products that researchers will need to conduct their research and study various diseases.

"There is tremendous excitement, especially in the academic community, over the recent Executive Order signed by President Barack Obama rescinding the restriction on federal funding of human embryonic stem cell research," notes Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. "However, the exploration of induced pluripotent stem cells and the pursuit of cell-based therapies and drug discovery and development research using adult human stem cells continues to provide great promise." Zemlo has been the senior analyst on over 80 syndicated market research reports, and consulted with multiple stem cell product vendors to optimize the relevance of this study with regards to the current stem cell research market.

To learn more about this report, a complimentary Executive Summary is available at


BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 43,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.

    For more information contact:

    Mary Follin
    Manager, Marketing/Sales
    BioInformatics, LLC
    2111 Wilson Blvd., Suite 250
    Arlington, VA  22201
    703.778.3080 x13 (phone)

SOURCE BioInformatics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals to Report First Quarter 2009 Results
2. Fovea Reports Positive Results with Prednisporin(TM) in Persistent Allergic Conjunctivitis
3. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
4. Des Moines Register Reports SpectraScience LUMA Enhances Cervical Cancer Exams
5. Clinician Reports Fast Healing of Intractable Wounds Using MEDIHONEY(R)
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
8. An Independent Study Reports on the Utility of ImmuKnow(R), the Cylex(TM) Immune Cell Function Assay, for Monitoring Heart Transplant Recipients
9. InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL)
10. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
11. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
Post Your Comments:
(Date:11/30/2015)... November 30, 2015 North America ... expected to grow at a CAGR of 7.6% from 2015 to ... at USD 135.6 million in 2014, and is expected to grow ... According to the new Market Research Report "North America Cardiac ... End User (Hospitals, ambulatory care, others) - Analysis And Forecast To ...
(Date:11/30/2015)...  Kevin Smith has been appointed Chief Commercial ... in wireless monitoring of vital signs.  As CCO ... Mr. Smith will be responsible for the development ... will also directly oversee partnering with US hospitals ... SensiumVitals, the first early warning detection device to ...
(Date:11/30/2015)... SAN DIEGO , Nov. 30, 2015 ... ) today announced that the U.S. Food and Drug ... Application (NDA) for an extended release formulation of lorcaserin. ... a chronic weight management treatment in a once-daily dosing ... as an adjunct to a reduced-calorie diet and increased ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ChiliPad , ... to maximize recovery through quality sleep. Tim DiFrancesco, training coach for the LA ... night’s sleep. ChiliPad precisely regulates the surface temperature of each side of the ...
(Date:11/30/2015)... ... 2015 , ... Using a combination of two blood sugar tests rather than ... to a new study by researchers at the School of Public Health at Georgia ... Combinations of Blood Glucose Tests ,” published in Frontiers in Public Health, the researchers ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ Top Dentist”, ... Tufts School of Dental Medicine in 1935. His father graduated from NYU School ... in dentistry as well as their commitment and passion to the Practice of Dentistry. ...
(Date:11/30/2015)... New York, NY (PRWEB) , ... November 30, 2015 , ... ... New York Times,” will be released on December 1, 2015, to coincide with World ... book about the groundbreaking journalist who covered the AIDS epidemic as he was dying ...
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for Clinical ... of World AIDS Day 2015. On Nov. 30, ASCP shared its “Give a minute. ... World AIDS Day and the importance of getting tested for HIV. , ASCP has ...
Breaking Medicine News(10 mins):